CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $714 | +2.7% | 14,514 | +17.3% | 0.00% | -33.3% |
| Q2 2023 | $695 | +24.1% | 12,372 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $560 | -24.3% | 12,372 | -32.0% | 0.00% | -25.0% |
| Q4 2022 | $740 | -99.9% | 18,207 | 0.0% | 0.00% | -42.9% |
| Q3 2022 | $1,190,000 | +183.3% | 18,207 | +163.2% | 0.01% | +250.0% |
| Q2 2022 | $420,000 | -3.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $434,000 | -17.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $524,000 | -32.3% | 6,917 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $774,000 | -30.9% | 6,917 | 0.0% | 0.00% | -40.0% |
| Q2 2021 | $1,120,000 | +32.9% | 6,917 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $843,000 | -20.4% | 6,917 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $1,059,000 | +82.9% | 6,917 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $579,000 | +14.0% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $508,000 | – | 6,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |